Sunho Biologics (SEHK:2898) - Stock Price, News & Analysis

2898 Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems.

About the company

2898 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue grew by 5.4% over the past year

Risk Analysis

Does not have meaningful revenue (CN¥12M)

Volatile share price over the past 3 months

Sunho Biologics, Inc. Competitors

3D Medicines

SEHK:1244

HK$740.8m

Genor Biopharma Holdings

SEHK:6998

HK$851.7m

Brii Biosciences

SEHK:2137

HK$855.3m

JW (Cayman) Therapeutics

SEHK:2126

HK$638.9m

Price History & Performance

Summary of all time highs, changes and price drops for Sunho Biologics
Historical stock prices
Current Share Price	HK$5.18
52 Week High	HK$15.42
52 Week Low	HK$4.20
Beta	0
11 Month Change	-24.27%
3 Month Change	-26.52%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-64.33%

Recent updates

Shareholder Returns

	2898	HK Biotechs	HK Market
7D	-9.9%	8.5%	10.9%
1Y	n/a	-7.9%	13.4%

Return vs Industry: Insufficient data to determine how 2898 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 2898 performed against the Hong Kong Market.

Price Volatility

Is 2898's price volatile compared to industry and market?
2898 volatility
2898 Average Weekly Movement	10.8%
Biotechs Industry Average Movement	7.4%
Market Average Movement	6.8%
10% most volatile stocks in HK Market	13.7%
10% least volatile stocks in HK Market	3.5%

Stable Share Price: 2898's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 2898's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Liusong Yin	www.sunho-bio.com.cn

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer (CRC). The company also provides IAP0971 and IAE0972 immunocytokines, which have completed Phase I clinical trials for advanced solid tumors, including non-small cell lung cancer and CRC.

Sunho Biologics, Inc. Fundamentals Summary

How do Sunho Biologics's earnings and revenue compare to its market cap?
2898 fundamental statistics
Market cap	HK$780.45m
Earnings (TTM)	-HK$118.92m
Revenue (TTM)	HK$12.83m

60.8x

P/S Ratio

-6.6x

P/E Ratio

Is 2898 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2898 income statement (TTM)
Revenue	CN¥11.57m
Cost of Revenue	CN¥0
Gross Profit	CN¥11.57m
Other Expenses	CN¥118.86m
Earnings	-CN¥107.29m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.71
Gross Margin	100.00%
Net Profit Margin	-927.14%
Debt/Equity Ratio	4.2%

How did 2898 perform over the long term?

See historical performance and comparison

Sunho Biologics SEHK:2898 Stock Report